What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study

International Journal of Cancer

Volumn 142, Issue 4, 2018, Pages 709-718

  Landy, Rebecca ^a   Windridge, Peter ^a   Gillman, Matthew S ^a   Sasieni, Peter D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cervical cancer; HPV; policy; screening; simulation; vaccination

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS PROTECTION; DRUG EFFICACY; FEMALE; HEALTH PROGRAM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MIDDLE AGED; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROBABILITY; PROTOCOL COMPLIANCE; SIMULATION; UNITED KINGDOM; UTERINE CERVIX CANCER; WANING VACCINE EFFICACY; YOUNG ADULT; ADOLESCENT; AGED; CHILD; COMPUTER SIMULATION; EARLY CANCER DIAGNOSIS; IMMUNOLOGY; PROCEDURES; STATISTICAL MODEL; UTERINE CERVIX TUMOR; VAGINA SMEAR; VERY ELDERLY; VIROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 85038866419     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.31094     Document Type: Article

References (30)

1. Clifford G, Franceschi S, Diaz M, et al. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24:S26–34.
2. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32.
3. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095–101.
4. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 2012;62:147–72.
5. Kim JJ, Tosteson AN, Zauber AG, et al. Cancer models and real-world data: better together. JNCIJ 2016;108:djv316
6. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506–11.
7. Bosch F, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244–65.
8. Office for National Statistics. Population Estimates by single year of age and sex for local authorities in the UK, mid-2015 2016 [cited 9th September 2016]. Available from https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland.
9. Kitchener H, Almonte M, Gilham C, et al. on behalf of the ARTISTIC Trial Study Group. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. 2009 Health Technology Assessment, Vol 13 No. 51.
10. Goldie SJ, Grima D, Kohli M, et al. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer 2003;106:896–904.
11. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621–32.
12. International Agency for Research on Cancer. In: Waterhouse J; Muir C; Shanmugaratnam K; Powell J, eds. Cancer incidence in five continents, volume IV. Lyon, 1982.
13. Clifford G, Smith J, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63–73.
14. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agents Cancer 2012;7:1
15. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009;199:926–35.
16. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:100–10.
17. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vacc Immunother 2014;10:2147–62.
18. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425–34.
19. Sasieni P, Castanon A, Parkin DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 2009;124:461–4.
20. Landy R, Pesola F, Castanon A, et al. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer 2016;115:1140–6.
21. Vink MA, Bogaards JA, Meijer CJ, et al. Primary human papillomavirus DNA screening for cervical cancer prevention: can the screening interval be safely extended? Int J Cancer 2015;137:420–7.
22. Australian Government: Department of Health. National Cervical Screening Programme: Future changes to cervical screening 2017 [cited 2017 24th May]. Available from: http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/content/future-changes-cervical.
23. Kim JJ, Burger EA, Sy S, et al. Optimal cervical cancer screening in women vaccinated against human papillomavirus. JNCI J Natl Cancer Inst 2017;109:
24. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA J Am Med Assoc 2003;290:781–9.
25. Naber SK, Matthijsse SM, Rozemeijer K, et al. Cervical cancer screening in partly HPV vaccinated cohorts–A cost-effectiveness analysis. PLoS One 2016;11:e0145548
26. Simms KT, Smith MA, Lew JB, et al. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer 2016;139:2771–80.
27. NHS England (prepared by PHE). NHS public health functions agreement 2016-17: Service specification No.11 Human papillomavirus (HPV) programme. 2016.
28. Kumar VM, Whynes DK. Explaining variation in the uptake of HPV vaccination in England. BMC Public Health 2011;11:(1):172.
29. Castle PE, Fetterman B, Poitras N, et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009;113:595.
30. Moss S, Gibney A. HPV primary screening pilots: evaluation report to the national screening committee. February 2015. Queen Mary University of London, 2015 Available from: https://legacyscreening.phe.org.uk/policydb_download.php?doc=560